Katherine Brito, MD
Ophthalmology · Geneva, ILNPI 1235371741
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Alcon at 29.3% of the total.
Across 46 payments — averaging $36.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$487
- Regeneron Healthcare Solutions, Inc.$285
- Rxsight Inc$248
- Genentech USA, Inc.$121
- Apellis Pharmaceuticals, Inc.$120
- Oyster Point Pharma, Inc.$97
- plus $301 from 8 others
What the payments were for
- Food & beverage$1,658100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 14 | $487 |
| Regeneron Healthcare Solutions, Inc. | 7 | $285 |
| Rxsight Inc | 5 | $248 |
| Genentech USA, Inc. | 5 | $121 |
| Apellis Pharmaceuticals, Inc. | 1 | $120 |
| Oyster Point Pharma, Inc. | 1 | $97 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $81 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $61 |
| Amgen | 1 | $35 |
| Ocular Therapeutix, Inc. | 2 | $29 |
| Novartis | 1 | $28 |
| Coherus Oncology, Inc. | 1 | $27 |
| Tarsus Pharmaceuticals, Inc. | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof$125
- Syfovre$120
- AcrySof IQ PanOptix UV IOL$102
- AcrySof IQ VIVITY$102
How this compares
$1,658 in reported general payments places this provider in the 55th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 15 | $17,410 |
| LumiganBimatoprost | 15 | $8,792 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,334 |
| Latanoprost | 153 | $1,299 |
| Prednisolone Acetate | 39 | $1,211 |
| MoxifloxacinMoxifloxacin Hcl | 24 | $698 |
| Timolol Maleate | 51 | $562 |
| ErythromycinErythromycin Base | 56 | $449 |
| Doxycycline Hyclate | 15 | $320 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 21 | $290 |
| Dorzolamide Hcl | 18 | $280 |
| Tobramycin | 11 | $36 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Geneva
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.